STOCK TITAN
  1. Home
  2. Sec-filings
  3. MDXL
  4. [NT 10-Q] MediXall Group, Inc. SEC Filing

MediXall Group (MDXL) discloses late Q2 2026 10-Q and multi-year backlog

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
NT 10-Q

Rhea-AI Filing Summary

MediXall Group, Inc. notified the SEC that it will file its Form 10-Q for the period ended June 30, 2026 late, citing that certain financial and other information could not be prepared within the deadline without unreasonable effort or expense. The company indicated it does not anticipate any significant change in results of operations versus the same period last year in the upcoming report. MediXall also disclosed it is delinquent on multiple prior reports, including the 2024 and 2025 Forms 10-K and several Forms 10-Q for periods in 2025 and early 2026, which are still being prepared for submission.

Positive

  • None.

Negative

  • Extensive SEC reporting delinquencies disclosed, including missing 2024 and 2025 Forms 10-K and multiple 2025–2026 Forms 10-Q, indicating ongoing compliance and reporting delays.
  • Current Q2 2026 Form 10-Q will not be filed on time, with no Rule 12b-25(b) assurance it will be submitted within the standard 5-day grace period.

Filing Explained

The notice seeks a five-calendar-day Rule 12b-25 filing window, while the June 30 interim financial statements and liquidity update remain unavailable.

This is a Form 12b-25 late-filing notice rather than the Form 10-Q for the period ended June 30, 2026; the company says certain information was not ready without unreasonable effort or expense and seeks the rule’s five-calendar-day filing window.

A Form 10-Q is the unaudited quarterly report containing interim financial statements and updates to risks and liquidity. The practical consequence is that this filing changes the timetable but does not provide the June 30 interim financial statements or liquidity figures; those remain to be disclosed in the Form 10-Q.

The stated resolution is filing the subject Form 10-Q on or before the fifth calendar day following its prescribed due date; this notice does not state that the report has been filed.

Subject period end June 30, 2026 Period covered by the delayed Form 10-Q
Delinquent annual reports 2024 Form 10-K and 2025 Form 10-K Annual reports not yet filed as disclosed by the company
Delinquent quarterly reports March 31, 2025; June 30, 2025; September 30, 2025; March 31, 2026 Quarterly reports on Form 10-Q still outstanding
Notification date August 14, 2026 Date the late-filing notification was signed by the CFO
Form 12b-25 regulatory
"FORM 12b-25 | NOTIFICATION OF LATE FILING"
Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.
Rule 12b-25 regulatory
"seeks relief pursuant to Rule 12b-25(b)"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.
transition report regulatory
"transition report on Form 10-K, Form 20-F, Form 11-K, Form 10-Q"
Section 13 or 15(d) regulatory
"periodic reports required under Section 13 or 15(d) of the Securities Exchange Act"
unreasonable effort or expense financial
"could not be provided within the prescribed time period without unreasonable effort or expense"

FAQ

Why did MediXall Group (MDXL) file an NT 10-Q for June 30, 2026?
MediXall Group filed an NT 10-Q because financial and other information needed for the Form 10-Q for the period ended June 30, 2026 could not be completed on time without unreasonable effort or expense.

Does MediXall Group (MDXL) expect major earnings changes in the delayed Q2 2026 report?
MediXall Group stated it does not anticipate any significant change in results of operations from the corresponding period last year in the earnings statements that will be included in the delayed Form 10-Q.

Which SEC reports is MediXall Group (MDXL) currently delinquent in filing?
MediXall reported it is delinquent on the 2024 Form 10-K, Forms 10-Q for March 31, June 30, and September 30, 2025, the 2025 Form 10-K, and the Form 10-Q for March 31, 2026.

Has MediXall Group (MDXL) filed all required SEC periodic reports in the past 12 months?
No. MediXall answered “No” to having filed all required periodic reports, listing multiple delinquent Forms 10-K and 10-Q from 2024 through early 2026 that are still being prepared.

Will MediXall Group (MDXL) file the Q2 2026 Form 10-Q within the Rule 12b-25 grace period?
MediXall checked only the Rule 12b-25 paragraph (c) box and did not check paragraph (b), so it did not represent that the Q2 2026 Form 10-Q will be filed within the usual 5-day grace period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

       
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  
     
 
   
  FORM 12b-25

SEC FILE NUMBER

333-194337

  NOTIFICATION OF LATE FILING

CUSIP NUMBER

 

 

                             
(Check one):  Form 10-K     Form 20-F     Form 11-K  ü   Form 10-Q     Form 10-D     Form N-CEN     Form N-CSR

 

         
  For Period Ended:  June 30, 2026
     
     Transition Report on Form 10-K
     
     Transition Report on Form 20-F
     
     Transition Report on Form 11-K
     
     Transition Report on Form 10-Q
     
  For the Transition Period Ended:  
     

 

 
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
PART I — REGISTRANT INFORMATION

 

 
MediXall Group, Inc.
Full Name of Registrant
 
 
Former Name if Applicable
 
104 N 4th St.
Address of Principal Executive Office (Street and Number)
 
Leesburg, FL 34748
City, State and Zip Code

 

 

 
 
 

 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

           
        (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
ü
 
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 
PART III — NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)
 
Certain financial and other information necessary for an accurate and full completion of the Report could not be provided within the prescribed time period without unreasonable effort or expense.

 

 
PART IV — OTHER INFORMATION

 

                   
(1) Name and telephone number of person to contact in regard to this notification
 
  Travis Jackson   800   381-1787
  (Name)   (Area Code)   (Telephone Number)
 
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes    No  ü  
 

 

The Company is delinquent in filing the 2024 Form 10-K, the Form 10-Q for the periods ended March 31, 2025, June 30, 2025 and September 30, 2025; the 2025 Form 10-K, and the Form 10-Q for the period ended March 31, 2026. We are in the process of preparing the respective Form 10-K’s and Form 10-Q’s for filing with the Securities and Exchange Commission.

 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes    No  ü  
 
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.  
 

 

           
   
  MediXall Group, Inc.
  (Name of Registrant as Specified in Charter)
   
  has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
   
Date: August 14, 2026     By: /s/ Travis Jackson
          Travis Jackson, Chief Financial Officer
             

 

Source: View Original Filing on SEC EDGAR